MedTrace Logo

Cognitive Impairment and Neuropsychiatric Manifestations of Neurobrucellosis

NCT04301752 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 82

Last updated 2020-03-18

No results posted yet for this study

Summary

Brucellosis is a common zoonotic infection in many parts of the world including the Mediterranean and Middle Eastern countries.

Neurobrucellosis may develop at any stage of disease and may have widely variable manifestations, including encephalitis, meningoencephalitis, radiculitis, myelitis, peripheral and cranial neuropathies, subarachnoid hemorrhage, and psychiatric manifestations.

Conditions

  • Brucellosis

Interventions

DIAGNOSTIC_TEST

MoCA

Cognitive function was assessed by using MoCA score. Cognitive impairment was considered present when MoCA scores were \<26. Maximum score is 30.

Sponsors & Collaborators

  • Mansoura University Hospital

    lead OTHER

Principal Investigators

  • Esmael M Ahmed, MD · Assistant Prof of Neurology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-01
Primary Completion
2020-01-01
Completion
2020-03-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04301752 on ClinicalTrials.gov